登出

Houte Hans Van Sells 924 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Houte Hans Van 出售了 Nurix Therapeutics, Inc.（纳斯达克股票代码：NRIX）的 924 股股票

Defense World · 2023/02/03 05:41

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) CFO Houte Hans Van sold 924 shares of the firm's stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $11.78, for a total transaction of $10,884.72. Following the completion of the sale, the chief financial officer now owns 76,765 shares in the company, valued at approximately $904,291.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Nurix Therapeutics Trading Up 7.3 %

NASDAQ NRIX opened at $13.26 on Friday. Nurix Therapeutics, Inc. has a 12 month low of $7.52 and a 12 month high of $20.20. The company's 50 day simple moving average is $11.69 and its 200 day simple moving average is $13.45.

Get Nurix Therapeutics alerts:

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NRIX shares. HC Wainwright dropped their price target on shares of Nurix Therapeutics to $53.00 in a research note on Thursday, October 13th. SVB Leerink dropped their price target on shares of Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research note on Tuesday, December 13th. Finally, Morgan Stanley started coverage on shares of Nurix Therapeutics in a research note on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.90.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Nurix Therapeutics by 11.0% in the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after buying an additional 367,743 shares during the last quarter. State Street Corp grew its position in Nurix Therapeutics by 9.2% in the third quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after buying an additional 195,453 shares during the last quarter. Vanguard Group Inc. grew its position in Nurix Therapeutics by 2.3% in the third quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after buying an additional 49,370 shares during the last quarter. ARK Investment Management LLC grew its position in Nurix Therapeutics by 54.5% in the fourth quarter. ARK Investment Management LLC now owns 1,988,254 shares of the company's stock worth $21,831,000 after buying an additional 701,732 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its position in Nurix Therapeutics by 41.9% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company's stock worth $23,096,000 after buying an additional 538,570 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.

Nurix Therapeutics Company Profile

(Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

纽瑞克斯治疗公司股价上涨7.3%

纳斯达克指数上周五开盘报13.26美元。Nurix Treateutics，Inc.的12个月低点为7.52美元，12个月高位为20.20美元。该公司的50日简单移动均线切入位在11.69美元，200日简单移动均线切入位在13.45美元。

到达纽瑞克斯治疗公司警报：

分析师升级和下调评级

几位股票研究分析师对NRIX的股票发表了评论。在10月13日星期四的一份研究报告中，HC Wainwright将Nurix治疗公司的股票目标价下调至53.00美元。SVB Leerink在12月13日(星期二)的一份研究报告中将Nurix Treateutics的股票目标价从37.00美元下调至28.00美元，并对该股设定了“跑赢大盘”的评级。最后，摩根士丹利在10月11日(星期二)的一份研究报告中开始对纽瑞克斯治疗公司的股票进行报道。他们对该股给予了“同等权重”的评级和11.00美元的目标价。一名投资分析师对该股的评级为持有，七名分析师对该股的评级为买入。根据MarketBeat.com的数据，该股目前的平均评级为“中等买入”，平均目标价为32.90美元。

机构资金流入和流出

一些对冲基金最近改变了他们在该股的头寸。第三季度，贝莱德公司在纽瑞克斯治疗公司的股份增加了11.0%。贝莱德股份有限公司在上个季度增持了367,743股后，现在持有3,723,090股该公司股票，价值48,512,000美元。道富集团第三季度在Nurix Treeutics的头寸增加了9.2%。道富银行目前持有该公司2,312,224股股票，价值30,128,000美元，此前该公司在上一季度又购买了195,453股。先锋集团第三季度在Nurix治疗公司的地位增加了2.3%。先锋集团目前持有2,160,866股该公司股票，价值28,156,000美元，上一季度又购买了49,370股。方舟投资管理公司第四季度在Nurix Treeutics的头寸增加了54.5%。Ark Investment Management LLC现在持有该公司1,988,254股股票，价值21,831,000美元，上个季度又购买了701,732股。最后，贝恩资本生命科学投资者有限责任公司在第二季度将其在Nurix Treeutics的头寸增加了41.9%。贝恩资本生命科学投资者有限责任公司现在拥有1,822,883股该公司股票，价值23,096,000美元，在上个季度又购买了538,570股。机构投资者和对冲基金持有该公司91.33%的股票。

纽瑞克斯治疗公司简介

(获取评级)

Nurix治疗公司是一家生物制药公司，专注于治疗癌症和免疫疾病的小分子疗法的发现、开发和商业化。该公司开发了用于治疗复发或难治性B细胞恶性肿瘤的口服布鲁顿酪氨酸激酶(BTK)降解剂NX-2127；用于治疗复发或难治性B细胞恶性肿瘤和自身免疫性疾病的口服生物可用BTK降解剂NX-5948；以及口服可用于免疫肿瘤学适应症的Casitas B细胞性淋巴瘤原癌基因B(CBL-B)抑制剂NX-1607。

另请参阅

免费获取StockNews.com关于Nurix治疗的研究报告(NRIX)
凯西·伍兹的方舟创新ETF将在2023年反弹？
马伦汽车公司股票因利好消息而上涨
哈雷-戴维森公司的股票，是时候买入了吗？
Meta平台的底部已经到了，波动性还没有结束
阿拉斯加航空公司近期收益分析

接受《Nurix治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nurix Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Houte Hans Van Sells 924 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Houte Hans Van Sells 924 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics Trading Up 7.3 %

Analyst Upgrades and Downgrades

Institutional Inflows and Outflows

Nurix Therapeutics Company Profile

See Also

纽瑞克斯治疗公司股价上涨7.3%

分析师升级和下调评级

机构资金流入和流出

纽瑞克斯治疗公司简介

另请参阅

风险及免责提示

声明